Human leukocyte antigen A*11:01 presenting KRAS G12V neoantigen peptide (HLA-A*11:01/KRAS-G12V)

The HLA-A*11:01 presenting KRAS G12V neoantigen peptide is a specific peptide-major histocompatibility complex (pMHC) that serves as a critical target for cancer immunotherapy [1]. KRAS is a proto-oncogene frequently mutated in various cancers, with the G12V substitution being one of the most common drivers in pancreatic, colorectal, and lung adenocarcinomas [2]. In patients carrying the HLA-A*11:01 allele, the mutated KRAS G12V protein is processed into short peptides and presented on the cell surface by the HLA molecule [3]. This specific pMHC complex is recognized as "foreign" by the immune system, making it an ideal neoantigen target for T-cell receptor (TCR) engineered T-cell therapies and cancer vaccines [4]. Because the G12V mutation is absent in healthy tissues, targeting this complex offers high tumor specificity and potentially reduces off-target effects [5]. Current therapeutic strategies include TCR-T cell products like AFNT-211 and multi-peptide vaccines designed to elicit a robust cytotoxic T-lymphocyte response against cells displaying this complex [6]. The HLA-A*11:01 allele is particularly prevalent in East Asian populations, making this target highly relevant for regional precision medicine [7]. Successful targeting of this pMHC complex requires high affinity and specificity to avoid cross-reactivity with wild-type KRAS or other self-peptides [8].

Other names

HLA-A*11:01/KRAS G12V complexKRAS G12V neoantigen-HLA-A*11:01pMHC complex (KRAS G12V/HLA-A*11:01)KRAS G12V 7-16 peptide presented by HLA-A*11:01

Recognition of the peptide-MHC complex by engineered or endogenous T-cell receptors (TCRs), leading to the activation of cytotoxic T-lymphocytes and subsequent lysis of tumor cells expressing the KRAS G12V mutation [1, 3].